Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application

Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour

Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.

Study Overview

• Status: Withdrawn
• Conditions: Conjunctical Flora
• Intervention / Treatment: Drug: gatifloxacin, moxifloxacin

• Study Type: Interventional
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 48 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age- older than 50 years of age
• Diagnosis- Cataract or had cataract surgery

Exclusion Criteria:

• Systemic or topical antibiotic treatment within 30 days
• Use of systemic or topical steroids
• Active ocular infection
• Ocular surgery in the past 6 months
• Allergy to fluoroquinolones

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Antibiotic killing of conjunctival bacterial flora 1 hour after application

Collaborators and Investigators

• Sponsor: Stanford University
• Investigators: Principal Investigator: Christopher Ta, MD, Stanford University

Publications and helpful links

General Publications

• Mino de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol. 2005 Apr;139(4):730-3. doi: 10.1016/j.ajo.2004.10.007.
• Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Mino De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002 Nov;109(11):2036-40; discussion 2040-1. doi: 10.1016/s0161-6420(02)01236-8.
• Ta CN, He L, Nguyen E, De Kaspar HM. Prospective randomized study determining whether a 3-day application of ofloxacin results in the selection of fluoroquinolone-resistant coagulase-negative Staphylococcus. Eur J Ophthalmol. 2006 May-Jun;16(3):359-64.
• de Kaspar HM, Kreidl KO, Singh K, Ta CN. Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. J Glaucoma. 2004 Dec;13(6):507-9. doi: 10.1097/01.ijg.0000137872.19942.cf.
• Ta CN, Chang RT, Singh K, Egbert PR, Shriver EM, Blumenkranz MS, Mino de Kaspar H. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology. 2003 Oct;110(10):1946-51. doi: 10.1016/s0161-6420(03)00735-8.

Study record dates

Study Major Dates

• Study Start: April 1, 2007

Study Registration Dates

• First Submitted: April 25, 2007
• First Submitted That Met QC Criteria: April 26, 2007
• First Posted (Estimate): April 27, 2007

Study Record Updates

• Last Update Posted (Estimate): June 13, 2013
• Last Update Submitted That Met QC Criteria: June 12, 2013
• Last Verified: June 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Pharmaceutical Solutions; Ophthalmic Solutions; Moxifloxacin; Gatifloxacin
• Other Study ID Numbers: 8924